Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 6.944 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - sevikar is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 13.888 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sevikar is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hyprolose; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; iron oxide red - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; iron oxide red - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - hydrochlorothiazide, quantity: 25 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; hyprolose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; iron oxide red - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - doxycycline monohydrate, quantity: 52.05 mg (equivalent: doxycycline, qty 50 mg) - tablet, uncoated - excipient ingredients: hydrogenated castor oil; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; povidone; sodium starch glycollate - infections caused by the following micro-organisms: mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always elminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline, or in combination with topical agents.) borreliae (relapsing fever); calymmatobacterium (donovania) granulomatis (granuloma inguinale). infections caused by the following gram-negative micro-organisms: vibrio sp. (cholera); brucella sp. (brucellosis; in conjunction with streptomycin); yersinia pestis (plague); francisella tularensis (tularaemia); bartonella bacilliformis (bartonellosis); bacteriodes sp. when penicillin is contraindicated, doxycycline

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - doxycycline hyclate, quantity: 57.7 mg (equivalent: doxycycline, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; macrogol 4000 - infections caused by the following microorganisms: mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus): chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline alone or in combination with topical agents). borreliae (relapsing fever); calymmatobacterium (donovania) granulomatis (granuloma inguinale). infections caused by the following gram-negative microorganisms: vibrio sp. (cholera); brucella sp. (brucellosis, in conjunction with streptomycin); haemophilus ducreyi (chancroid); yersinia pestis (plague); francisella tularensis (tularaemia); bartonella bacilliformis (bartonellosis); bacteroides sp. when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: treponema pallidum (syphilis); treponema perenue (yaws); neisseria gonorrhoea (see dosage and administration). doxycycline is not the drug of choice in the treatment of any type of staphylococcal infection of infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, enterococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a b-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual drug of choice. in acute intestinal amoebiasis doxycycline may be a useful adjunct to amoebicides. in severe acne, doxycycline may be a useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p. vivax. as there are relatively few locations where p. vivax does not co-exist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine. note: the 50mg tablet is not a paediatric formulation.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - doxycycline hyclate, quantity: 115.4 mg (equivalent: doxycycline, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; macrogol 4000 - infections caused by the following organisms; mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline alone, or in combination with topical agents). borreliae (relapsing fever). calymmatobacterium (donovania) granulomatis (granuloma inguinale). infection caused by the following gram-negative microorganisms: vibrio species (chlorea), brucella sp. (brucellosis; in conjunction with streptomycin), haemophilus ducreyi (chancroid), yersinia pestis (plague), francisella turarenis (tularaemia), bartonella bacilliformis (bartonellosis), bacteroides sp. when penicillin is contraindicated, doxy-100 is an alternative drug in the treatment of infections due to : treponema pallidum (syphilis); treponema pertenue (yaws); neisseria gonorrhoea (see dosage and administration). doxy-100 is not the drug of choice in the treatment of any type of staphylococcal infection or infections due to streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxy-100 should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual drug of choice. in acute intestinal amoebiasis, doxycycline may be a useful adjunct to amoebicides. in severe acne, doxycycline may be useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p. vivax. as there are relatively few locations where p. vivax does not co-exist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example, chloroquine.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - doxylamine succinate, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; maize starch; lactose monohydrate; magnesium stearate; purified water - for temporary relief of sleeplessness

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - doxylamine succinate, quantity: 25 mg - tablet, uncoated - excipient ingredients: maize starch; microcrystalline cellulose; magnesium stearate; purified water; lactose monohydrate - for temporary relief of sleeplessness